290 related articles for article (PubMed ID: 25182639)
1. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
2. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5438-47. PubMed ID: 23959322
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
6. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
Ibrahim AS; Gebremariam T; French SW; Edwards JE; Spellberg B
J Antimicrob Chemother; 2010 Feb; 65(2):289-92. PubMed ID: 19942619
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.
Seyedmousavi S; Mouton JW; Melchers WJ; Verweij PE
Antimicrob Agents Chemother; 2015 Mar; 59(3):1487-94. PubMed ID: 25534731
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Ibrahim AS; Gebremariam T; Luo G; Fu Y; French SW; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2011 Apr; 55(4):1768-70. PubMed ID: 21263057
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
Mavridou E; Brüggemann RJ; Melchers WJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2010 Feb; 54(2):860-5. PubMed ID: 19917751
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.
Howard SJ; Lestner JM; Sharp A; Gregson L; Goodwin J; Slater J; Majithiya JB; Warn PA; Hope WW
J Infect Dis; 2011 May; 203(9):1324-32. PubMed ID: 21357943
[TBL] [Abstract][Full Text] [Related]
11. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6284-9. PubMed ID: 24100500
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
Andes D; Marchillo K; Conklin R; Krishna G; Ezzet F; Cacciapuoti A; Loebenberg D
Antimicrob Agents Chemother; 2004 Jan; 48(1):137-42. PubMed ID: 14693531
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
18. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
Barchiesi F; Santinelli A; Biscotti T; Greganti G; Giannini D; Manso E
J Antimicrob Chemother; 2016 Aug; 71(8):2230-3. PubMed ID: 27231274
[TBL] [Abstract][Full Text] [Related]
19. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Gebremariam T; Alkhazraji S; Gu Y; Najvar LK; Borroto-Esoda K; Patterson TF; Filler SG; Wiederhold NP; Ibrahim AS
Antimicrob Agents Chemother; 2024 May; 68(5):e0154523. PubMed ID: 38557112
[TBL] [Abstract][Full Text] [Related]
20. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
